A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
The entry-fusion process is one of the most promising targets to develop new classes of effective anti-HIV drugs but currently there are only two inhibitors of this class approved by the FDA and none of them binds to the envelope glycoprotein gp120. The situation is even worse for enterovirus EV71 infection for which no antiviral therapies are available. We describe here the discovery of potent entry dual inhibitors of HIV and EV71. These compounds contain in their structure 3 or 4 tryptophandoi:10.1021/acs.jmedchem.9b01737.s002 fatcat:vrymghnyhzf3lh5ngtn6fxuxja